Is It Too Late to Buy VBI Vaccines Shares?
Investors in VBI Vaccines (NASDAQ: VBIV) have been on a roller-coaster ride this year as the company tries to develop a safe and effective COVID-19 vaccine. After the stock rose more than 330% from its price at the start of 2020, it lost almost half of those gains in late July. Given that the company's products only earned it $200,000 in the second quarter, compared with $600,000 a year prior, investors might be concerned that its days as a growth stock are over.
Despite its weak position in the COVID-19 race, I think that VBI will grow in the future on the basis of the programs that were in its pipeline before 2020. In particular, its hepatitis B vaccine will soon deliver revenue even if its coronavirus vaccine candidate does not.
Image source: Getty Images.
Source Fool.com
